Provided are OLEDs and related electronic devices that utilize these OLED devices. The OLED includes an emissive region that includes a sensitizer and an acceptor, where the sensitizer has a lowest excitation energy state E.sub.T1, and is capable of harvesting triplet excitons; where the acceptor is capable of receiving energy from the sensitizer and functioning as a fluorescent emitter at room temperature; where the acceptor has a first moiety and a second moiety, the first moiety having a lowest singlet excitation energy state E.sub.S1.sup.A and a lowest triplet excitation energy state E.sub.T1.sup.A, and the second moiety having a lowest singlet excitation energy state E.sub.S1.sup.B and a lowest triplet excitation energy state E.sub.T1.sup.B; and where E.sub.S1.sup.A<E.sub.S1.sup.B, E.sub.T1.sup.A>E.sub.T1.sup.B, and E.sub.T1>E.sub.S1.sup.A.

YAP1 inhibitors and methods of treating a subject with a cancer that include administering a YAP1 inhibitor are disclosed. Also disclosed are methods for determining responsiveness to a YAP1 inhibitor in a subject, methods for diagnosing a tumor in a subject including determining the level of YAP1 expression, compositions that include YAP1 inhibitors, and methods of using those compositions.

YAP1 inhibitors and methods of treating a subject with a cancer that include administering a YAP1 inhibitor are disclosed. Also disclosed are methods for determining responsiveness to a YAP1 inhibitor in a subject, methods for diagnosing a tumor in a subject including determining the level of YAP1 expression, compositions that include YAP1 inhibitors, and methods of using those compositions.

The present disclosure relates to macrocyclic compounds, pharmaceutical compositions containing macrocyclic compounds, and methods of using macrocyclic compounds to treat disease, such as cancer.

The present disclosure relates to macrocyclic compounds, pharmaceutical compositions containing macrocyclic compounds, and methods of using macrocyclic compounds to treat disease, such as cancer.

The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

The present disclosure relates to hydroxypheophorbide compounds with bioactivities towards obesity and obesity-related co-morbidities. Therefore, the present subject-matter discloses hydroxypheophorbide compounds or a pharmaceutically acceptable salt, hydrate, solvate, N-oxide, stereoisomer, diastereoisomer, enantiomer or atropisomer, polymorph for use in medicine comprising formula (I), wherein R is C.sub.nH.sub.(2n-1) and n is an entire number multiple of 5. The compound of the present disclosure may be use in the therapy or treatment of obesity, an obesity-related disorder, an obesity related disease, being overweight, an obesity-related condition, or lipid obesity disorders.

##STR00001##

The present disclosure relates to hydroxypheophorbide compounds with bioactivities towards obesity and obesity-related co-morbidities. Therefore, the present subject-matter discloses hydroxypheophorbide compounds or a pharmaceutically acceptable salt, hydrate, solvate, N-oxide, stereoisomer, diastereoisomer, enantiomer or atropisomer, polymorph for use in medicine comprising formula (I), wherein R is C.sub.nH.sub.(2n-1) and n is an entire number multiple of 5. The compound of the present disclosure may be use in the therapy or treatment of obesity, an obesity-related disorder, an obesity related disease, being overweight, an obesity-related condition, or lipid obesity disorders.

##STR00001##

Disclosed herein are compositions comprising a water-soluble host-guest complex formed from a host receptor and a guest photosensitizer for the photoprotection of the photosensitizer. Also disclosed are methods of using the composition for generating reactive oxygen species, inhibiting the proliferation or killing of a cell, treating a subject with a cell proliferative disease or disorder.